

(21) Application No: **0902572.7**

(22) Date of Filing: **21.08.2008**

(30) Priority Data:

(31) 60957453	(32) 22.08.2007	(33) US
(31) 60957449	(32) 22.08.2007	
(31) 61052986	(32) 13.05.2008	

(86) International Application Data:
PCT/US2008/009974 En 21.08.2008

(87) International Publication Data:
WO2009/025846 En 26.02.2009

(71) Applicant(s):
The Regents of the University of California
111 Franklin Street, 12th Floor, Oakland,
California 94607-5200,
United States of America

CytomX LLC
460 Ward Drive, Suite E-1, Santa Barbara,
California 93111, United States of America

(continued on next page)


(51) INT CL:
C07K 14/00 (2006.01) **A61K 39/395** (2006.01)
C07K 16/28 (2006.01) **C07K 19/00** (2006.01)
C12N 15/10 (2006.01)

(56) Documents Cited by ISA:
WO 2005/051315 A2 **WO 2005/042034 A1**
US 20060228348 A1 **US 20030021791 A1**
Palandoken, H et al., "Amiloride peptide conjugates: Prodrugs for sodium-proton exchange inhibition", Journal of Pharmacology and Experimental Therapeutics, Vol. 312, No. 3, Oct 2004, pages 961-967.

(58) Field of Search by ISA:
 INT CL **A61K, C07K**
 Other: **Pubmed, Esp@snet, Delphion**

(54) Abstract Title: **Activatable binding polypeptides and methods of indentification and use thereof**

(57) The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an "activatable" conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.



GB 2455449 A continuation

(72) Inventor(s):

**Patrick Daugherty
Nancy Stagliano
Jerry Thomas
Kathryn Kamath
James W West
Sanjay Khare**

(74) Agent and/or Address for Service:

**Mewburn Ellis LLP
33 Gutter Lane, LONDON, EC2V 8AS,
United Kingdom**